The Harrington Discovery Institute at University Hospitals in Cleveland is partnering with the University of Oxford and a U.K.-based investment company to launch a transatlantic therapeutics accelerator aimed at developing treatments for rare diseases.
The Oxford-Harrington Rare Disease Centre Therapeutics Accelerator is a first-in-kind initiative to identify, fund and advance breakthrough academic discoveries for rare genetic diseases — such as rare neurological diseases, cancers and developmental diseases — affecting some 400 million children and adults worldwide, the partners said Tuesday.
The accelerator partners, which include Oxford Science Enterprises, announced the accelerator’s launch on Tuesday during a signing event at the University of Oxford.
Full story: UH partners with University of Oxford on developing treatments for rare diseases – cleveland.com
